Summary
Preconditioning has been shown to reduce cell death, although the mechanism responsible is still unclear. Activation of phosphatidylinositol-3-kinase (PI3K) has been shown to be cardioprotective. This paper will review the data suggesting a role for the PI3K pathways in cardioprotection and preconditioning. The PI3K pathway is activated by preconditioning and inhibition of PI3K blocks the protective effects of preconditioning. Thus, enhanced cell survival via activation of PI3K appears to be important in preconditioning.
Key words
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Murry C, Jennings R, Reimer K. 1986. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74:1124–1136.
Steenbergen C, Perlman M, London R, Murphy E. 1993. Mechanism of preconditioning: ionic alterations. Circ Res 72:112–125.
Liu G, Thornton J, Van Winkle D, Stanley A, Olsson R, Downey J. 1991. Protection against infarction afforded by preconditioning is mediated by Al adenosine receptors in rabbit heart. Circ Res 84:350–356.
Bolli T, Black RJ, Kodani E, Tang X, Yang Z, Bhattacharya S, Auchampach J. 2001. A(1) or A(3) adenosine receptors induce late preconditioning against infarction in conscious rabbits by different mechanisms. Circ Res 88:520–528.
Goto M, Liu Y, Yang X, Ardell J, Cohen M, Downey J. 1995. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res 77:611–621.
Thornton J, Liu G, Downey J. 1993. Pretreatment with pertussis toxin blocks the protective effects of preconditioning: evidence for a G-protein mechanism. J Mol Cell Cardiol 25:311–320.
Schultz J, Hau A, Barbieri J, Li P, Gross G. 1998. Pertussis toxin abolishes the cardioprotective effect of ischemic preconditioning in intact rat heart. Am J Physiol 275:H495–H500.
Ytrehus K, Liu Y, Downey J. 1994. Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am J Physiol 266:H1145–H1152.
Speechly-Dick M, Mocanu M, Yellon D. 1994. Protein kinase C: its role in ischemic preconditioning in the rat. Circ Res 75:586–590.
Chen W, Wetsel W, Steenbergen C, Murphy E. 1996. Effect of ischemic preconditioning and PKC activation on acidification during ischemia in rat heart. J Mol Cell Cardiol 28:871–880.
Ping P, Zhang J, Qui Y, Tang X, Manchikalapudi S, Cao X, Bolli R. 1997. Ischemic preconditioning induces selective translocation of protein kinase C isoforms ε and η in the heart of conscious rabbits without subcellular redistribution of total protein kinase C activity. Circ Res 81:404–414.
Dorn G, Souroujon M, Liron T, Chen C, Gray M, Zhou H, Csukai M, Wu G, Lorenz J, Mochly-Rosen D. 1999. Sustained in vivo cardiac protection by a rationally designed peptide that causes epsilon protein kinase C translocation. Proc Natl Acad Sci 96:12798–12803.
Pass J, Zheng Y, Wead W, Zhang J, Li R, Bolli R, Ping P. 2001. PKCepsilon activation induces dichotomous cardiac phenotypes and modulates PKCepsilon-FACK interaction and RACK expression. Am J Physiol 280:H946–H955.
Cross H, Murphy E, Bolli R, Ping P, Steenbergen C. 2000. Expression of activated PKC-epsilon protects the ischemic heart, without attenuating ischemic H+ production. J Mol Cell Cardiol.
Auchampach J, Grover G, Gross G. 1992. Blockade of ischemic preconditioning in dogs by the novel ATP dependent potassium channel antagonist sodium 5-hydroxydecanoate. Cardiovas Res 26:1054–1062.
Liu Y, Sato T, O’Rourke B, Marban E. 1998. Mitochondrial ATP dependent potassium channels: novel effectors of cardioprotection? Circulation 97:2463–2469.
Garlid K, Paucek P, Yarv-Yarovoy V, Murray H, Darbenzio R, D’alonzo A, Lodge N, Smith M, Grover G. 1997. Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K+ channels: possible mechanism of cardioprotection. Circ Res 81:1072–1082.
Forbes R, Steenbergen C, Murphy E. 2001. Diazoxide-induced cardioprotection requires signaling through a redox-sensitive mechanism. Circ Res 88:802–809.
Murphy E, Glasgow W, Fralix T, Steenbergen C. 1995. Role of lipoxygenase metabolites in ischemic preconditioning. Circ Res 76:457–467.
Chen W, Glasgow W, Murphy E, Steenbergen C. 1999. Lipoxygenase metabolism of arachidonic acid in ischemic preconditioning and PKC-induced protection in heart. Am J Physiol 276:H2094–H2101.
Starkopf J, Andreasen T, Bugge E, Ytrehus K. 1998. Lipid peroxidation, arachidonic acid and products of the lipoxygenase pathway in ischemic preconditioning of rat heart. Cardiovasc Res 37:66–75.
Gabel S, London R, Funk C, Steenbergen C, Murphy E. 2001. Leukocyte-type 12-lipoxygenase-deficient mice show impaired ischemic preconditioning-induced cardioprotection. Am J Physiol 280:H1963–H1969.
Wu W, Lee W, Wu Y, Chen D, Liu T, Jang A, Sharma P, Wang P. 2000. Expression of constitutively active phosphatidylinositol 3-kinase inhibits activation of caspase 3 and apoptosis of cardiac muscle cells. J Biol Chem 275:40113–40119.
Matsui T, Li L, del Monte F, Fakui Y, Franke T, Hajjar R, Rosenzeig A. 1999. Adenovirus gene transfer of activated phosphatidyhnositol-3′-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes in vitro. Circulation 100:2373–2379.
Yamashita K, Kajstura J, Discher D, Wasserlauf B, Bishopric N, Anversa P, Webster K. 2001. Re-perfusion-activated Akt kinase prevents apoptosis in transgenic mouse hearts overexpressing insulin-like growth factor. Circ Res 88:609–614.
Rameh L, Cantley L. 1999. The role of phosphoinositide-3-kinase lipid products in cell function. J Biol Chem 274:8347–8350.
Murry C, Richard VJ, Reimer K, Jennings R. 1990. Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode. Circ Res 66:913–931.
Weiss R, de Albuquerque C, Vandegaer K, Chacko V, Gerstenblith G. 1996. Attenuated glycogenol-ysis reduces glycolytic catabolite accumulation during ischemia in preconditioned hearts. Circ Res 79:435–446.
Tong H, Chen W, Steenbergen C, Murphy E. 2000. Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C. Circ Res 87:309–315.
Alessi D, Cohen P. 1998. Mechanism of activation and function of protein kinase B. Curr Opin Genet Dev 8:55–62.
Harada H, Anderson J, Mann M, Terada N, Korsmeyer S. 2001. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci 98:9666–9670.
Ping P, Takano H, Zhang J, Tang X, Qui Y, Li R, Banerjee S, Dawn B, Balafonova Z, Bolli R. 1999. Isoform-selective activation of protein kinase C by nitric oxide in the heart of conscious rabbits: a signaling mechanism for both nitric oxide-induced and ischemia-induced preconditioning. Circ Res 84:587–604.
Takano H, Tang X, Qui Y, Guo Y, French B, Bolli R. 1998. Nitric oxide donors induce late preconditioning against myocardial stunning and infarction in conscious rabbits via an antioxidant-sensitive mechanism. Circ Res 83:73–84.
Woolfson R, Patel V, Neild G, Yellon D. 1995. Inhibition of nitric oxide synthesis reduces infarct size by an adenosine dependent mechanism. Circulation 91:1545–1551.
Weselcouch E, Baird A, Sleph P, Grover G. 1995. Inhibition of nitric oxide synthesis does not affect ischemic preconditioning in isolated perfused rat heart. Am J Physiol 268:H242–H249.
Wei G, Zweier J. 2001. Endothelial nitric oxide synthase is essential for acute ischemic preconditioning. FASEB J 15:A465.
Tong H, Imahashi K, Steenbergen C, Murphy E. 2002. Phosphorylation of glycogen synthase kinase 3 β during preconditioning through a phosphatidylinositol-3-kinase-dependent pathway is cardioprotective. Circ Res 90:in press.
Aikawa R, Nawana M, Gu Y, Katagiri H, Asano T, Zhu W, Nagaki R, Komuro I. 2000. Insulin prevents cardiomyocytes from oxidative stress-induced apoptosis through activation of Pi3 kinase/Akt. Circulation 102:2873–2979.
Jonassen A, Sacks M, Mjos O, Yellon D. 2001. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res 89:1191–1198.
Mehrhof F, Muller F, Bergmann M, Li P, Wang Y, Schmitz W, Dietz R, Harsdorf R. 2001. In car-diomyocyte hypoxia, insulin-like growth factor-I-induced antiapoptotic signaling requires phosphatidylinositol-3-OH-kinase-dependent adn mitogen-activated protein kinase-dependent activation of the transcription factor cAMP response element-binding protein. Circulation 104:2088–2094.
Negoro S, Oh H, Tone E, Kunisada K, Fujio Y, Walsh K, Kishimoto T, Yamauchi-Takihara K. 2001. Glycoprotein 130 regulates cardiac myocyte survival in doxorubicin-induced apoptosis through phosphatidylinositol-3-kinase/Akt phosphorylation and Bcl-xL/caspase 3 interaction. Circulation 103:555–561.
Zhu W, Zheng M, Koch W, Lefkowitz R, Kobilka B, Xiao R. 2001. Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci 98:1607–1612.
Chesley A, Lundberg M, Asai T, Xiao R, Ohtani S, Lakatta E, Crow M. 2000. The beta(2)-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3′-kinase. Circ Res 87:1172–1179.
Guerra S, Leri A, Wang X, Finato N, Di Loreto C, Beltrami C, Kajstura J, Anversa P. 1999. Myocyte death in the failing human heart is gender dependent. Circ Res 85:856–866.
Kirkwood F, Sueta C, Gheorghiade M, O’Connor C, Schwartz T, Koch G, Uretsky B, Swedberg K, McKenna W, Soler-Soler J, Califf R. 1999. Gender differences in survival in advanced heart failure, insights from the FIRST study. Circulation 99:1816–1821.
Camper-Kirby D, Welch S, Walker A, Shiraishi I, Setchell K, Schafer E, Katjstura J, Anversa P, Sussman M. 2001. Myocardial Akt activation and gender: increased nuclear activity in females versus males. Circ Res 88:1020–1027.
Naga Prasad S, Esposito G, Mao L, Koch W, Rochman H. 2000. Gbetagamma-dependent phos-phoinositide 3-kinase activation in hearts with in vivo pressure overload hypertrophy. J Biol Chem 275:4693–4698.
Morisco C. 2000. The Akt-glycogen synthase kinase 3beta pathway regulates the transcription of atrial natriuretic factor induced by beta-adrenergic receptor stimulation. J Biol Chem 275: 14466–14475.
Haq S. 2000. Glycogen synthase kinase 3beta is a negative regulator of cardiomyocyte hypertrophy. J Cell Biol 151:117–130.
Harding V, Jones L, Lefkowitz R, Koch W, Rockman H. 2001. Cardiac β APJCl inhibition prolongs survival and augments β blocker therapy in a mouse model of severe heart failure. Proc Natl Acad Sci 98:5809–5814.
Antos C, McKinsey T, Frey N, Kutschke W, McAnally J, Shelton J, Pichardson J, Hill J, Olsen E. 2002. Activated glycogen synthase-3 β supresses cardiac hypertrophy in vivo. Proc Natl Acad Sci.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this chapter
Cite this chapter
Murphy, E., Tong, H., Steenbergen, C. (2003). A Role for the Phosphatidylinositol-3-Kinase Pathway in Preconditioning. In: Dhalla, N.S., Takeda, N., Singh, M., Lukas, A. (eds) Myocardial Ischemia and Preconditioning. Progress in Experimental Cardiology, vol 6. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0355-2_19
Download citation
DOI: https://doi.org/10.1007/978-1-4615-0355-2_19
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5036-1
Online ISBN: 978-1-4615-0355-2
eBook Packages: Springer Book Archive